Maintenance Rucaparib for Platinum-Sensitive Pancreatic Adenocarcinoma with HRD-Associated Mutations
Results of a phase II study in patients with germline or somatic pathogenic variants in BRCA1/2 or PALB2
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
EMA Recommends Extension of Indications for Venetoclax
New indication concerns combination treatment with a hypomethylating agent in adult patients with newly diagnosed AML who are ineligible for intensive chemotherapy
Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic Cervical Carcinoma
The EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 study met the primary endpoint of overall survival
Activity of Targeted/Immune Therapy Approach in Patients with Advanced Urothelial Cancer
Findings from the BISCAY study
FDA Grants Accelerated Approval to Pembrolizumab for HER2-positive Gastric Cancer
Approval is based on findings from prespecified interim analysis of ongoing KEYNOTE-811 study
Most Cases of Venous Thromboembolic Events, Elevated Aminotransferases, and Interstitial Lung Disease Are Manageable in Patients Receiving Adjuvant Abemaciclib for Early Breast Cancer
Adverse events associated with abemaciclib were characterised in patients participating in the phase III open-label monarchE study
Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients with HER2-positive Metastatic Breast Cancer
Close monitoring needed to allow earlier identification and effective management of interstitial lung disease
Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2 Blockade in HER2-positive/HR-negative Early Breast Cancer
Translational findings from the WSG-ADAPT study
Risk of Distant Recurrence of ER-Positive Breast Cancer in Premenopausal Women According to 70-Gene Risk Signature
Swedish investigators found that clinical benefit with endocrine therapy differs by risk group
Neoadjuvant Pertuzumab/Trastuzumab Demonstrates Long-Term Cardiac Safety in HER2-Positive Breast Cancer
No new safety signals occurred with neoadjuvant pertuzumab/trastuzumab at five years
Biomarker Data from the KAITLIN Study in High-Risk Early Breast Cancer
AC-KP did not result in improved efficacy in any reasonably sized biomarker subgroup
Reassuring Results Observed with Shorter Duration of Adjuvant Trastuzumab in HER2-positive Early Breast Cancer
Non-inferiority with the short- versus long-term adjuvant trastuzumab could not be claimed